Long-term protection of hepatitis B vaccine 18 years after vaccination - 08/08/11
Corresponding author. Tel.: +966 1 4671215; fax: +966 1 4671217.Summary |
Introduction |
This is the third evaluation study of the hepatitis B virus (HBV) vaccination program, initiated in 1989 in Saudi Arabia.
Aims |
This study sought to assess the efficacy and long-term protection of the hepatitis B vaccine among Saudi adolescents.
Methods |
School students between the ages of 16 and 18 years were randomly chosen from high endemic (Aseer), intermediate endemic (Madinah), and low endemic (Al-Qaseem) areas of the country. Hepatitis B surface antigen (HBsAg), hepatitis B core IgG antibody (anti-HBc), and hepatitis B surface antibody (anti-HBs) were measured using standard techniques.
Results |
A total of 1355 students (689 males and 666 females) were selected randomly from the three areas. No cases of positive HBsAg or anti-HBc were detected among the study population. Five hundred and ten students (38%) showed protective anti-HBs titers (≥10mIU/ml), while 528 (39%) students had undetectable anti-HBs titers (<1mIU/ml).
Conclusions |
This study shows the excellent efficacy of the HBV vaccination program in Saudi Arabia 18 years after its launch. Based on this study and others, a booster dose for the adult population appears to be unnecessary.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatitis B, Saudi Arabia, Epidemiology, Prevalence, Vaccination, Vaccine, Long-term
Plan
Vol 57 - N° 5
P. 404-409 - novembre 2008 Retour au numéro
Article précédent
- Influence of brucellosis history on serological diagnosis and evolution of patients with acute brucellosis
- María de los Ángeles Mantecón, María Purificación Gutiérrez, María del Pilar Zarzosa, Luis Fernández-Lago, Juan de Dios Colmenero, Nieves Vizcaíno, Miguel Angel Bratos, Ana Almaraz, África Cubero, Maria Fe Muñoz, A. Rodríguez Torres, Antonio Orduña
- Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin
- R.M. Gallagher, B. Pizer, J.A. Ellison, F.A.I. Riordan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?